作者
Ian A Scott, Sarah N Hilmer, Emily Reeve, Kathleen Potter, David Le Couteur, Deborah Rigby, Danijela Gnjidic, Christopher B Del Mar, Elizabeth E Roughead, Amy Page, Jesse Jansen, Jennifer H Martin
发表日期
2015/5/1
期刊
JAMA internal medicine
卷号
175
期号
5
页码范围
827-834
出版商
American Medical Association
简介
Inappropriate polypharmacy, especially in older people, imposes a substantial burden of adverse drug events, ill health, disability, hospitalization, and even death. The single most important predictor of inappropriate prescribing and risk of adverse drug events in older patients is the number of prescribed drugs. Deprescribing is the process of tapering or stopping drugs, aimed at minimizing polypharmacy and improving patient outcomes. Evidence of efficacy for deprescribing is emerging from randomized trials and observational studies. A deprescribing protocol is proposed comprising 5 steps: (1) ascertain all drugs the patient is currently taking and the reasons for each one;(2) consider overall risk of drug-induced harm in individual patients in determining the required intensity of deprescribing intervention; (3) assess each drug in regard to its current or future benefit potential compared with current or future harm or …
引用总数
20152016201720182019202020212022202320243110414017119417520018418980
学术搜索中的文章